Hansa Biopharma AB (HNSBF)
3.65
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Hansa Biopharma Enterprise Value: 278.10M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 278.10M |
| November 12, 2024 | 278.10M |
| November 11, 2024 | 278.10M |
| November 08, 2024 | 278.10M |
| November 07, 2024 | 278.10M |
| November 06, 2024 | 278.10M |
| November 05, 2024 | 278.10M |
| November 04, 2024 | 278.10M |
| November 01, 2024 | 278.10M |
| October 31, 2024 | 278.10M |
| October 30, 2024 | 278.10M |
| October 29, 2024 | 278.10M |
| October 28, 2024 | 278.10M |
| October 25, 2024 | 278.10M |
| October 24, 2024 | 278.10M |
| October 23, 2024 | 278.10M |
| October 22, 2024 | 278.10M |
| October 21, 2024 | 230.86M |
| October 18, 2024 | 230.86M |
| October 17, 2024 | 230.86M |
| October 16, 2024 | 230.86M |
| October 15, 2024 | 230.86M |
| October 14, 2024 | 230.86M |
| October 11, 2024 | 230.86M |
| October 10, 2024 | 230.86M |
| Date | Value |
|---|---|
| October 09, 2024 | 230.86M |
| October 08, 2024 | 230.86M |
| October 07, 2024 | 230.86M |
| October 04, 2024 | 230.86M |
| October 03, 2024 | 230.86M |
| October 02, 2024 | 230.86M |
| October 01, 2024 | 230.86M |
| September 30, 2024 | 230.86M |
| September 27, 2024 | 215.89M |
| September 26, 2024 | 215.89M |
| September 25, 2024 | 215.89M |
| September 24, 2024 | 215.89M |
| September 23, 2024 | 215.89M |
| September 20, 2024 | 215.89M |
| September 19, 2024 | 215.89M |
| September 18, 2024 | 215.89M |
| September 17, 2024 | 215.89M |
| September 16, 2024 | 215.89M |
| September 13, 2024 | 215.89M |
| September 12, 2024 | 215.89M |
| September 11, 2024 | 215.89M |
| September 10, 2024 | 215.89M |
| September 09, 2024 | 215.89M |
| September 06, 2024 | 215.89M |
| September 05, 2024 | 215.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
118.23M
Minimum
Dec 19 2023
1.231B
Maximum
Jul 27 2020
389.99M
Average
230.86M
Median
Sep 30 2024
Enterprise Value Benchmarks
| Abliva AB | 11.86M |
| Oncopeptides AB | -- |
| BioInvent International AB | 215.05M |
| BioArctic AB | 1.160B |
| Camurus AB | 3.067B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.00M |
| Revenue (Quarterly) | 4.689M |
| Total Expenses (Quarterly) | 15.96M |
| EPS Diluted (Quarterly) | -0.1475 |
| Gross Profit Margin (Quarterly) | 76.62% |
| Profit Margin (Quarterly) | -213.3% |
| Earnings Yield | -29.56% |
| Normalized Earnings Yield | -29.56 |